RE:Useful Actionable information from Hulot............ You want useful information RADish. Here it is:
CXR is a unique opportunity. If you have enough patience and balls, this investment has the potential for huge gains. I have already explained the reasons for the downturn in earlier posts. Bad timing. Bad Luck. Then the Company when into shock and a tailspin. Like a chicken without its head so to speak. You’d know that right, Lattice. Take a look at recent history: With almost the same fundamentals CXR was $65 only 15 months ago. Let's say the company conservatively makes $3 per share as analysts estimate in 2017. 50/3=16.7 PE that is lower than the average PE in the Pharma industry. This is crazy for this stock. Let's assume the market is forward looking, basing a decision on analyst assessments. If leading analysts put 2017 at EPS $3, then why are market estimates giving a share price below $3? Huge opportunity. Any chance for Bankruptcy? Sure, but not earlier than four years. If Bankruptcy is not on the horizon than I conclude THIS IS THE CHEAPEST PHARMA STOCK ON THE PLANET.